Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:4.2.1.22 (cystathionine beta-synthase)
965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The previously published procedure (Kraus et al. (1978) J. Biol. Chem. 253, 6523-6528) for the purification of cystathionine beta-synthase [L-serine hydro-lyase (adding homocysteine) EC 4.2.1.22], a pyridoxal 5'-phosphate-dependent enzyme from human liver has been modified. The new procedure, starting with a liver homogenate "aged" for 7 days at 4 degrees C, yielded homogeneous enzyme purified over 3000-fold with a much improved yield. "Aging" of the enzyme in crude homogenates yields a form apparently smaller by gel electrophoresis and with significantly increased activity and antigenicity. This species of cystathionine beta-synthase does not form stable complexes with other proteins during purification as does the previously employed, freshly used species. An absorption spectrum and an amino acid composition of the pure enzyme were determined; the amino-terminal residue was shown to be methionine. The isoelectric points of holosynthase and aposynthase were estimated to be 5.2 and 5.6, respectively. Rabbit antiserum raised against the pure cystathionine beta-synthase was characterized using as antigen crude synthase from five different mammalian species as well as the pure human enzyme.
...
PMID:Cystathionine beta-synthase from human liver: improved purification scheme and additional characterization of the enzyme in crude and pure form. 683 28

The treatment of homocystinuria that is not responsive to pyridoxine is not usually biochemically or clinically successful, and vascular, ocular, and skeletal complications commonly supervene. Persistent marked homocysteinemia appears to be the most important biochemical disturbance leading to these complications. Ten patients with cystathionine beta-synthase deficiency that was not responsive to pyridoxine and one patient with homocystinuria due to a defect in cobalamin metabolism were treated with 6 g daily of betaine added to conventional therapy, to improve homocysteine remethylation. All patients had a substantial decrease in plasma total homocysteine levels (P less than 0.001) and an increase in total cysteine levels (P less than 0.001). Changes in plasma methionine concentrations were variable. Fasting levels of plasma amino acids became normal in two patients, and in six there was immediate clinical improvement. There were no unwanted effects. We conclude that treatment of homocystinuria that is not responsive to pyridoxine and of disorders of homocysteine remethylation should include betaine in adequate doses to ensure maximum lowering of elevated plasma homocysteine levels.
...
PMID:Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine. 687 13

In order to ascertain the role of L-serine sulfhydro-lyase (L-serine hydro-lyase (adding homocysteine) EC 4.2.1.22) which also catalyzes sulfhydrylation of O-acetyl-L-serine (Yamagata, S. (1981) J. Bacteriol. 147, 688-690), the enzyme was partially purified from a wild-type strain and three cysteine auxotrophs of Saccharomyces cerevisiae, and the molecular and enzymatic properties of these preparations were compared. The results showed no significant difference in properties investigated, indicating that cysteine synthesis is exclusively performed in this organism through sulfhydrylation of O-acetyl-L-serine, catalyzed not by serine sulfhydro-lyase but by O-acetylserine . O-acetylhomoserine sulfhydro-lyase (Yamagata, S., Takeshima, K. and Naiki, N. (1974) J. Biochem. 75, 1221-1229). Insensitivity of the former enzyme to L-methionine also supported this conclusion.
...
PMID:Partial purification and comparison of some properties of L-serine sulfhydro-lyase of Saccharomyces cerevisiae. 703 82

There is as yet no satisfactory experimental model for homocystinuria due to cystathionine beta-synthase deficiency. We produced homocysteinemia in pigs for up to 60 days by continuously infusing DL-homocysteine thiolactone and compared the changes in the plasma amino acids with the findings in 16 patients with homocystinuria. Vascular morphology was also investigated in the infused animals. In six pigs DL-homocysteine thiolactone, 0.68/kg/day for 13-60 days increased mean levels of methionine from 43.6 to 116.6 mumole/l, homocystine from zero to 67.4, cysteine-homocysteine disulfide from 4.3 to 49.2, taurine from 97.3 to 193.9 and alpha-amino-n-butyric acid from 16.5 to 147.4. Total cysteine did not change although cystine decreased from 50.8 to 26.2 mumole/liter. There were no amino acid changes in four saline infused (control) pigs and no differences in vascular morphology between experimental and control animals. Seven severely affected homocystinuric patients, biochemically, unresponsive to pyridoxine administration, had plasma sulfur-containing amino acid changes of similar magnitude to those in the infused pigs except that taurine concentrations were normal and total cysteine was decreased as it also was in nine pyridoxine responsive patients. In contrast to the pigs, plasma alpha-amino-n-butyric acid was normal in all 16 patients. We conclude that this model provides information about methionine metabolism but that it should be used with caution to study mechanisms in homocystinuria because it does not exactly mimic the human disease and because the thiolactone, which at present must be used as the source of infused L-homocysteine, itself produces changes which could influence results.
...
PMID:Experimental homocysteinemia in pigs: comparison with studies in sixteen homocystinuric patients. 709 48

The ability of human skin-fibroblasts in monolayer culture to carry out transsulphuration and remethylation of homocysteine has been tested. The conversion of homocyst(e)ine ot cyst(e)ine and methionine was studied in control and mutant cells by incubation for 16 h with L-[35S] homocystine. Labelled cysteic acid and methionine sulphone were found in hydrolysates of oxidized cell proteins. The quantities found were dependent on the time of incubation and were used as a measure of cyst(e)ine and methionine formation, respectively. In control cells, labelled cyst(e)ine and labelled methionine were found. In cystathionine beta-synthase-deficient cell lines, labelled cyst(e)ine formation was reduced, while labelled methionine formed was similar to that of controls, indicating the role of transsulphuration in the formation of cyst(e)ine observed in control cells. In a 5,10-methylenetetrahydrofolate reductase-deficient cell line, labelled methionine formation was reduced, indicating the role of N-5-methyltetrahydrofolate-requiring methylation of homocysteine in the formation of methionine observed in control cells.
...
PMID:Transsulphuration and methylation of homocysteine in control and mutant human fibroblasts. 713 17

1. Twenty-eight male rats of initial age 27 d were fed on fortified-barley diets for 3 weeks. In all experimental diets, both crude protein (nitrogen x 6.25) and methionine:cystine were constant at 120.0 g/kg dry matter (DM) and 2:1 respectively. The basal diet contained 4.5 g methionine plus cystine/kg DM with L-methionine plus L-cystine (2:1, w/w) added in increments of 0.5 g/kg DM to a final level of 7.0 methionine plus cystine/kg DM. A 'positive-control' diet of barley plus 193.7 g soya-bean meal/kg DM contained 6.0 g methionine plus cystine/kg DM. 2. Weight gain, food conversion efficiency (FCE), urinary urea-N excretion, carcass composition and activities of liver cystathionine synthase (EC 4.2.1.22) and N5-methyltetrahydrofolate-homocysteine-methyltransferase (EC 2.1.1.13) were determined. 3. Weight gain, food consumption, FCE and carcass composition measurements of rats showed either small or no differences between the experimental diets containing 4.5--7.0 g methionine plus cystine/kg DM. For the over-all period, weight gain and FCE of rats receiving the 'positive control' diet were significantly higher than values obtained with rats receiving any of the experimental diets. 4. Cystathionine synthase activity (mumol/mg protein per 60 min; units) increased from 13.38 at 4.5 g dietary methionine plus cystine/kg DM to 18.81 at 5.0 g dietary methionine plus cystine/kg DM. The activity was then inhibited to reach a minimum value of 10.16 units at the 6.0 g/kg DM dietary level. Thereafter the activity increased to a value of 30.00 units at 7.0 g dietary methionine plus cystine/kg DM. 5. The activity of N5-methyltetrahydrofolate-methyltransferase was constant at 0.70--0.74 nmol/mg protein per 60 min between dietary levels of 4.5 and 5.0 g methionine plus cystine/kg DM. The activity then increased to a maximum value of 2.32 nmol/mg protein per 60 min at the 6.0 g/kg DM level. Thereafter the activity decreased, reaching a minimum value of 0.70 nmol/mg protein per 60 min at the 7.0 g methionine plus cystine/kg level. 6. Urinary urea-N excretion decreased significantly from 1.07 g/kg DM intake at the 4.5 g dietary methionine plus cystine/kg DM level to 1.05 g/kg DM at the 5.0 g/kg dietary level, then dropped significantly to a level of 1.01--1.00 g/kg DM intake for the higher levels of dietary methionine plus cystine.
...
PMID:Growth and liver enzyme response in growing rats to graded levels of methionine plus cystine in fortified-barley diets. Response at constant methionine:cystine. 737 Feb 12

Hepatic cystathionine beta-synthase activity is decreased by the addition of cysteine to the diet. This effect of cysteine was slightly greater in diets containing 0.25% methionine than in those containing 1% methionine, and was reduced during aging. Similar changes were observed in the level of the mRNA of this enzyme, although the changes in the transcript levels were slightly greater than the changes in enzyme activity. Thus, we conclude that the addition of cysteine to a methionine-containing diet causes a decrease in cystathionine beta-synthase activity mainly by diminishing its mRNA level.
...
PMID:Effect of cysteine on expression of cystathionine beta-synthase in the rat liver. 756 13

Serine acetyltransferase (SATase; EC 2.3.1.30), which catalyzes the reaction connecting serine and cysteine/methionine metabolism, plays a regulatory role in cysteine biosynthesis in plants. We have isolated a cDNA clone encoding SATase by direct genetic complementation of a Cys- mutation in Escherichia coli using an expression library of Citrullus vulgaris (watermelon) cDNA. The cDNA encodes a polypeptide of 294 amino acids (31,536 Da) exhibiting 51% homology with that of E. coli SATase. DNA-blot analysis indicated the presence of a single copy of the SATase gene (sat) in watermelon. RNA hybridization analysis suggested the relatively ubiquitous and preferential expression in the hypocotyls of etiolated seedlings. Immunoblot analysis indicated the accumulation of SATase predominantly in etiolated plants. L-Cysteine, an end product of the cysteine biosynthetic pathway, inhibited the SATase in an allosteric manner, indicating the regulatory function of SATase in this metabolic pathway, whereas beta-(pyrazole-1-yl)-L-alanine, a secondary metabolite formed partly through the cysteine biosynthetic pathway, showed no inhibitory effect. A multi-enzyme complex was formed from recombinant proteins of SATase and cysteine synthase (O-acetylserine(thiol)-lyase) from watermelon, suggesting efficient metabolic channeling from serine to cysteine, preventing the diffusion of intermediary O-acetyl-L-serine.
...
PMID:Molecular cloning and characterization of a plant serine acetyltransferase playing a regulatory role in cysteine biosynthesis from watermelon. 760

Deficiency of cystathionine beta-synthase (CBS) is a genetic disorder of transsulfuration resulting in elevated plasma homocyst(e)ine and methionine and decreased cysteine. Affected patients have multisystem involvement, which may include light skin and hair. Reversible hypopigmentation in treated homocystinuric patients has been infrequently reported, and the mechanism is undefined. Two CBS-deficient homocystinuric patients manifested darkening of their hypopigmented hair following treatment that decreased plasma homocyst(e)ine. We hypothesized that homocyst(e)ine inhibits tyrosinase, the major pigment enzyme. The activity of tyrosinase extracted from pigmented human melanoma cells (MNT-1) that were grown in the presence of homocysteine was reduced in comparison to that extracted from cells grown without homocysteine. Copper sulfate restored homocyst(e)ine-inhibited tyrosinase activity when added to the culture cell media at a proportion of 1.25 mol of copper sulfate per 1 mol of DL-homocysteine. Holo-tyrosinase activity was inhibited by adding DL-homocysteine to the assay reaction mixture, and the addition of copper sulfate to the reaction mixture prevented this inhibition. Other tested compounds, L-cystine and betaine did not affect tyrosinase activity. Our data suggest that reversible hypopigmentation in homocystinuria is the result of tyrosinase inhibition by homocyst(e)ine and that the probable mechanism of this inhibition is the interaction of homocyst(e)ine with copper at the active site of tyrosinase.
...
PMID:Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: the mechanism for reversible hypopigmentation in homocystinuria due to cystathionine beta-synthase deficiency. 761 Dec 81

Direct sequencing of the coding region of the cystathionine beta-synthase (CBS) gene in two homocystinuric patients revealed the presence of two novel missense mutations. The first mutation, a 1111G-->A transition, resulted in the substitution of the evolutionary conserved valine-371 by a methionine residue (V371M) and created a new NlaIII restriction site. The second mutation, a G-->A transition at base-pair 494, resulted in an amino acid change from cysteine to tyrosine (C165Y) and abolished a BsoFI restriction site. Both mutations were found in a compound heterozygous state with the previously described 833T-->C transition.
...
PMID:Two novel missense mutations in the cystathionine beta-synthase gene in homocystinuric patients. 763 85


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---